. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: J Allergy Clin Immunol. 2013 Jan;131(1):119–127.e7. doi: 10.1016/j.jaci.2012.11.011

Table 1.

Baseline Characteristics

	Treatment
	Placebo (N=20)	Peanut SLIT (N=20)
	%	%
Male Gender	70.0	65.0
Additional Food Allergy	70.0	85.0
Physician Diagnosis Asthma	60.0	55.0
Allergic Rhinitis	75.0	70.0
	Median [Q1, Q3]	Median [Q1, Q3]
Age (years)	16.0 [13.5,18.5]	14.0 [13.0,18.0]
Baseline Atopic Dermatitis Total Score	0.0 [0.0,1.5]	0.0 [0.0,3.0]
Baseline Peanut Endpoint Titer	2000 [200,20000]	2000 [1100,11000]
Baseline Skin Prick Test Peanut Score (mm)	12.0 [9.0,16.5]	13.3 [9.5,17.5]
Baseline Peanut IgE (kU_A/L)	22.5 [3.3,77.7]	31.3 [3.2,42.4]
Baseline OFC Dose at First Symptom (mg)	6.0 [3.5,71.0]	6.0 [1.0,46.0]
Baseline OFC Successfully Consumed Dose (mg)	71.0 [3.5,196.0]	21.0 [1.0,146.0]